http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20120098436-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_259045c6eba6e2c5d338b84e0a88b571 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 |
| filingDate | 2012-02-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9aed347e47c13fbd9e98bc3fb3b4223b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df2c32782ccecbab94e24d66130f7755 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2f9da7233a719240981be4726f5113b6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2cc4e4451742364a25d79400c0085d86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_be70075294f2c4052dff261977f50253 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9513705683ced6f758137e059b74f633 |
| publicationDate | 2012-09-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20120098436-A |
| titleOfInvention | A pharmaceutical composition for inhibiting cancer metastasis or inhibiting cancer metastasis, comprising an inhibitor for the expression or activity of the MAP7 protein, a novel cancer treatment target. |
| abstract | The present invention relates to a pharmaceutical composition for treating cancer or inhibiting cancer metastasis, which comprises a novel cancer treatment target MAP7D2 protein expression or activity inhibitor as an active ingredient. Through the mining technique, a novel targeting anticancer candidate target was identified, and based on the gene expression pattern in the cancer cell line, an appropriate cancer cell line was selected and experimentally verified through the inhibition of the target candidate gene, through which MAP7D2 was renal cancer. Novel anticancer agents by overexpressing in various cancer tissues or cancer cells such as lung cancer, colorectal cancer, ovarian cancer, gastric cancer and liver cancer, inhibiting MAP7D2 growth, migration, invasion and metastasis of cancer cells and inducing apoptosis Since the possibility of MAP7D2 was identified as a target of MAP7D2, the expression level of MAP7D2 was used. Diagnose, it can be effectively used as an active ingredient of the therapeutic or cancer metastasis inhibiting pharmaceutical composition of the expression or activity inhibitors of protein MAP7D2 cancer. |
| priorityDate | 2011-02-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 549.